PATENT CLAIM ANALYSIS

Application Number: 15962752
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["424", "139100"]

Abstract:
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Claim (Index 235):
The method of  claim 211 , further comprising administering an anti-PD-1 antibody or an anti-OX40 antibody to the subject who has received the antibody that specifically binds to human GITR;\n wherein the anti-PD-1 antibody or the anti-OX40 antibody is administered at a time at which the anti-GITR antibody has increased expression of PD-1 or OX40 in the subject relative to expression of PD-1 or OX40 in the subject at the time of the administering.

Metadata:
- Claim Count in Document: 123.0
- Percentile: 91.0
- Lexical Diversity: 1.74545
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15962673', '14724452', '14472116', '11389880', '12753402']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7783621434427528
- 35 USC 102 Novelty (BERT): 0.6033572850611144
- Combined Prediction Score: 0.760861657604589
- Mean Citation Score: 539.2658939999999
- Max Citation Score: 687.7104
- Similarity Product: 432.47249418125153

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test